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a b s t r a c t
Mixed phenotype acute leukemia is a rare subtype of leukemia that probably arises from a
hematopoietic pluripotent stem cell. The co-expression of two of myeloid, B- or T-lymphoid
antigens is the hallmark of this disease. Herein, the case of a 28-year-old female patient is
reported who presented with hemoglobin of 5.8 g/dL, white blood cell count of 138×109/L
and platelet count of 12×109/L. The differential count of peripheral blood revealed 96%
of blasts. Moreover, the patient presented with lymphadenopathy, splenomegaly and bone
marrow inﬁltration by monocytoid blasts characterized as 7% positivity by Sudan Black cyto-
chemical staining. Immunophenotyping revealed the involvement of blasts of both T- and
monocytic lineages. The cytogenetic analysis showed an isolated 17p deletion. Thus, the
diagnosis of T-cell/myeloid mixed phenotype acute leukemia was made with two particular
rare features, that is, the monocytic differentiation and the 17p deletion as unique cyto-
genetic abnormalities. The possibility of concomitant expressions of T-cell and monocytic
differentiation antigens in the same blast population is hard to explain using the classical
model of hematopoiesis. However, recent studies have suggested thatmyeloid potential per-
sists even when the lineage branches segregate toward B- and T-cells. The role of an isolated
17p deletion in the pathogenesis of this condition is unclear. At present, the patient is in
complete remission after an allogeneic stem cell transplantation procedure.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Avenida José Bastos, 3390, 60431-086 Fortale
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Figure 1 – Bone marrow aspirate: blasts exhibit a
monocytoid nuclear aspect and ﬁne chromatin with a
prominent nucleoli.294 rev bras hematol hem
Introduction
Mixed phenotype acute leukemia (MPAL) is a heteroge-
neous group of rare and poorly differentiated diseases
that comprises about 2–5% of all acute leukemias.1,2 This
kind of leukemia can be classiﬁed as B-cell/myeloid, T-
cell/myeloid, B/T-lymphoid and, more rarely, as trilineage
B-cell/T-cell/myeloid.3 The T-cell/myeloid phenotype repre-
sents 35% of all MPAL.4
Most MPAL cases have been associated with cytogenetic
aberrations, mainly complex karyotypes. The t(9;22) and
11q23/MLL rearrangements are the most common recurrent
abnormalities. Unlike acute myeloid leukemia, with recurrent
genetic abnormalities, the role of cytogenetic aberrations in
the pathophysiology of MPAL remains unclear.4
Herein, the case of a patient with T-cell/myeloid acute
leukemia with monocytic differentiation and an isolated 17p
deletion is reported.
Case report
A 28-year-old female was admitted with a 3-week history
of asthenia, fever, odynophagia and purpura. On physi-
cal examination, neck lymphadenopathy (the largest being
1.5 cm), hepatomegaly (3 cmbelow the right costalmargin) and
splenomegaly (10 cm below the left costal margin) were found.
The results of laboratory tests were as follows: hemoglobin
concentration was 5.8 g/dL and white blood cell count was
138×109/L. The platelet count was 12.0×109/L. A peripheral
blood smear revealed 96% of blasts. Serology for B and C hep-
atitis, HIV, and HTLV-I/II virus were all negative.
A bone marrow aspirate was performed for ﬂow cytometry,
cytogenetics and molecular biology studies. The bone marrow
aspirate was hypercellular with 98% of medium- to large-sized
blasts, a high nuclear-to-cytoplasmic ratio and basophilic
cytoplasm. The nuclei were irregular, with a monocytoid
aspect in most cells, and ﬁne chromatin with a prominent
nucleoli (Figure 1). Sudan Black cytochemical staining was
positive in only 7% of blasts.
Three-color multiparameter ﬂow cytometry analysis was
performed in aCoulter EPICSXL-MCLﬂowcytometer equipped
with an argon ion laser using the erythrocyte lyse-wash prepa-
rationmethod. Immunophenotyping revealed the existence of
a unique population of blast cells that were positive for both
monocytic and T-lineage differentiation. The blasts exhibited
co-expression of monocytic differentiation markers, CD11c
and CD64, together with the CD7 antigen (Figure 2). More-
over, the blasts were positive for the speciﬁc T-cell lineage
intracytoplasmic CD3 (cCD3). The blasts were also positive for
CD13, CD33, partial CD34, CD38, CD45weak, CD117 and par-
tial myeloperoxidase; they were negative for CD1a, CD2, CD4,
CD5, CD8, CD10, CD11b, CD14, CD19, CD56, CD61, CD79a and
HLA-DR.
Cytogenetic analysis by G-banding showed a
46,XX,del(17)(p11.2) karyotype (Figure 3). Molecular anal-
ysis by polymerase chain reaction (PCR) of the BCR/ABL1,
TEL/AML1 and MLL/AF4 fusion genes were all negative.
The patient was treated at the beginning with the frac-
tionated cyclophosphamide, vincristine, Adriamycin, anddexamethasone (Hyper-CVAD) regimen and achieved hemato-
logical remission. However, at the end of the initial treatment,
minimal residual diseasemeasured by ﬂow cytometry showed
the presence of 0.03% T-cell/myeloid blasts in the bone mar-
row. Thus, allogeneic stemcell transplantationwas performed
and, at present, the patient is in complete hematological
remission.
Discussion
The 2008 WHO classiﬁcation of mixed phenotype acute
leukemia is based on the expression of strictly speciﬁc mark-
ers. Thus, for myeloid/monocytic lineage to be established,
unequivocal myeloperoxidase positivity is necessary or at any
rate, clear evidence of monocytic differentiation, which is
characterized by the expression of at least two of the fol-
lowing markers: nonspeciﬁc esterase, CD11c, CD14, CD64 or
lysozyme. The involvement of the T-cell lineage is determined
by the expression of cCD3. The patient of the current study
presented with blasts that only partially expressed myeloper-
oxidase by ﬂow cytometry. On the other hand, the blasts
clearly showed co-expression for cCD3 and the associated
monocytic markers, CD11c and CD64, which immediately
characterizes this case as T-cell/myeloid mixed phenotype
acute leukemia with monocytic differentiation in accordance
with the 2008 WHO classiﬁcation.5
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Figure 2 – Flow cytometric analysis of bone marrow sample
at diagnosis. Blasts show co-expression of CD11c and CD64
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Figure 3 – G-banding chromosome analysis showing
isolated del(17)(p11.2). Thus, based on the 2008 revision of
the WHO classiﬁcation of myeloid neoplasms and acute
leukemia,5 a diagnosis of MPAL, T-cell/myeloid with antigens together with CD7 and are also positive for cCD3
nd CD33 antigens.
Mixed phenotype acute leukemia is an uncommon entity.1
he T-cell/myeloid phenotype represents about one-third of
ll patients with the diagnosis of MPAL.4,6 Moreover, cases of
-cell/myeloid acute leukemia with monocytic differentiation
re even rarer.monocytic component was made.
Thus, in a recent published series of 100 cases of MPAL,
Matutes et al. reported only four cases with CD14 expression
and 13 cases showing positivity for lysozyme.4 Owaidah et al.,
using the criteria of the European Group for Immunopheno-
typing of Leukemias (EGIL), published 23 cases of biphenotypic
acute leukemia (BAL) with none expressing CD14, although
the CD64 antigen was expressed in three cases and the CD11b
was found in seven.6 However, it is important to underscore
that none of these authors mentioned whether there was con-
comitant expression of at least two monocytic markers in
the leukemic cells as required by the WHO classiﬁcation, and
thus, it is actually unclear whether monocytic differentiation
was really present in these series. In fact, out of 20 cases of
T-cell/myeloid acute leukemia recently published in the liter-
ature, only one clearly proved monocytic differentiation.3
Interestingly, the monocytic component of the cur-
rent MPAL case cannot be easily explained by the classic
model of binary split differentiation between lymphoid and
myelomonocytic lineages and, indeed, it is hard to justify
the existence of both T-cell and monocytic involvement in
the same leukemic cell. However, recent evidence has shed
some light on this intricate question suggesting that in the
early stages of hematopoiesis, the separation of the B-cell
and T-cell lymphoid lineages may occur prior to the loss of
myeloid/macrophage potential.7 Moreover, early T-cell pre-
cursors, a subset of thymocytes, are recent immigrants from
the bone marrow to the thymus that retain multilineage dif-
ferentiation potential, which suggests their direct derivation
from hematopoietic stem cells. So, we could hypothesize that
T-cell/monocytic leukemia cells arise from an immature pre-
cursor before the loss of myeloid differential potential.8,9
With regard to cytogenetic ﬁndings, chromosomal abnor-
malities were shown to be present in 68–91% of the cases
of MPAL/BAL.4,6 Rubnitz et al. reported 35 cases of MPAL; in
the T-cell/myeloid subgroup, there were just three cases with
abnormalities of chromosome 17, namely, t(17,19), ins(15,17)
and −17, all of them in a complex karyotype.2 Thus, as far
as we know, there are no previously published cases of T-
cell/myeloid MPAL with isolated 17p deletion in the literature.
In general, the 17p deletion is seen in 3–4%of acutemyeloid
leukemia and myelodysplastic syndromes, and confers a poor
prognosis10 probably due to inactivation of the p53 gene a
tumor suppression gene that plays an important role in the
oter.
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control of apoptosis. Approximately 32% of acute leukemia
cases with del(17p) have p53 mutations. Higher percentages
have been found in other hematologic malignancies.11 The
role of the 17p deletion in the prognosis of MPAL remains
unclear.
In summary, this is a case of T-cell/myeloid MPAL with
two extremely rare features: monocytic differentiation and
isolated 17p deletion.
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